eyes-10q_20190331.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

 

Commission File Number 001-36747

Second Sight Medical Products, Inc.

(Exact name of Registrant as specified in its charter)

 

California

 

02-0692322

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

12744 San Fernando Road, Suite 400, Sylmar, CA 91342

(Address of principal executive offices, including zip code)

 

(818) 833-5000

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes    No 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

Emerging growth company

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).      Yes    No 

 

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.     Yes      No  

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock

 

EYES

 

NASDAQ

Warrants

 

EYESW

 

NASDAQ

 

 

 

 

 

As of May 10, 2019, the registrant had 124,197,961 shares of common stock, $0 par value per share and 61,459,657 warrants, outstanding.

 

 

 

 


 

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

 

FORM 10-Q

TABLE OF CONTENTS 

 

PART I

FINANCIAL INFORMATION

 

 

 

 

Item 1.

Financial Statements

 

 

 

 

 

Condensed Consolidated Balance Sheets as of March 31, 2019 (unaudited) and December 31, 2018

3

 

Condensed Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018 (unaudited)

4

 

Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2019 and 2018 (unaudited)

5

 

Condensed Consolidated Statements of Stockholders’ Equity for each of the three-month periods ended March 31, 2019 and 2018 (unaudited)

6

 

Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018 (unaudited)

7

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

25

 

 

 

Item 4.

Controls and Procedures

25

 

 

 

PART II

OTHER INFORMATION

 

 

 

 

Item 1.

Legal Proceedings

26

 

 

 

Item 1A.

Risk Factors

26

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

28

 

 

 

Item 3.

Defaults Upon Senior Securities

28

 

 

 

Item 4.

Mine Safety Disclosures

28

 

 

 

Item 5.

Other Information

28

 

 

 

Item 6.

Exhibits

29

 

 

 

SIGNATURES

30

 

2


 

Part I. Financial Statements

Item 1. Financial Statements

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Balance Sheets

(in thousands)

 

 

 

March 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

 

 

(unaudited)

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

31,682

 

 

$

4,471

 

Accounts receivable, net

 

 

597

 

 

 

504

 

Inventories, net

 

 

1,602

 

 

 

3,250

 

Prepaid expenses and other current assets

 

 

1,155

 

 

 

1,395

 

Total current assets

 

 

35,036

 

 

 

9,620

 

Property and equipment, net

 

 

963

 

 

 

1,025

 

Right-of-use assets

 

 

2,508

 

 

 

 

Deposits and other assets

 

 

41

 

 

 

37

 

Total assets

 

$

38,548

 

 

$

10,682

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,600

 

 

$

1,305

 

Accrued expenses

 

 

2,309

 

 

 

2,503

 

Accrued compensation expense

 

 

2,080

 

 

 

2,690

 

Accrued clinical trial expenses

 

 

1,016

 

 

 

933

 

Current operating lease liabilities

 

 

210

 

 

 

 

Contract liabilities

 

 

218

 

 

 

167

 

Total current liabilities

 

 

7,433

 

 

 

7,598

 

Long term operating lease liabilities

 

 

2,586

 

 

 

 

Total liabilities

 

 

10,019

 

 

 

7,598

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, no par value, 10,000 shares authorized; none outstanding

 

 

 

 

 

 

Common stock, no par value; 200,000 shares authorized; shares issued and

   outstanding: 124,198 and 76,336 as of March 31, 2019 and December 31,

   2018, respectively

 

 

263,418

 

 

 

229,019

 

Additional paid-in capital

 

 

46,586

 

 

 

44,111

 

Accumulated other comprehensive loss

 

 

(583

)

 

 

(575

)

Accumulated deficit

 

 

(280,892

)

 

 

(269,471

)

Total stockholders’ equity

 

 

28,529

 

 

 

3,084

 

Total liabilities and stockholders’ equity

 

$

38,548

 

 

$

10,682

 

 

See accompanying notes.

3


 

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Statements of Operations (unaudited)

(in thousands, except per share data)

 

 

 

Three Months Ended

March 31,

 

 

 

2019

 

 

2018

 

Net sales

 

$

1,128

 

 

$

976

 

Cost of sales

 

 

731

 

 

 

668

 

Gross profit

 

 

397

 

 

 

308

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development, net of grants

 

 

2,183

 

 

 

2,474

 

Clinical and regulatory

 

 

1,006

 

 

 

1,348

 

Selling and marketing

 

 

2,103

 

 

 

3,011

 

General and administrative

 

 

2,449

 

 

 

3,244

 

      Impairment charge

 

 

2,424

 

 

 

 

Total operating expenses

 

 

10,165

 

 

 

10,077

 

Loss from operations

 

 

(9,768

)

 

 

(9,769

)

Interest income

 

 

68

 

 

 

16

 

Net loss

 

$

(9,700

)

 

$

(9,753

)

Net loss per common share – basic and diluted

 

$

(0.10

)

 

$

(0.17

)

Weighted average common shares outstanding – basic and diluted

 

 

96,567

 

 

 

59,052

 

 

See accompanying notes.

4


 

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Statements of Comprehensive Loss (unaudited)

(in thousands)

 

 

 

Three Months Ended

March 31,

 

 

 

2019

 

 

2018

 

Net loss

 

$

(9,700

)

 

$

(9,753

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

Foreign currency translation adjustments

 

 

(8

)

 

 

45

 

Comprehensive loss

 

$

(9,708

)

 

$

(9,708

)

 

See accompanying notes.

5


 

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

(in thousands)

 

 

 

Common Stock

 

 

Common Stock

Issuable

 

 

Additional

Paid-in

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balance, December 31, 2017

 

 

57,630

 

 

$

202,156

 

 

 

82

 

 

$

153

 

 

$

40,522

 

 

$

(572

)

 

$

(234,377

)

 

$

7,882

 

Issuance of shares of common

   stock, net of issuance costs

 

 

2,224

 

 

 

3,992

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,992

 

Warrants exercise

 

 

5

 

 

 

7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

7

 

Common stock issuance for

   services

 

 

 

 

 

 

 

 

34

 

 

 

65

 

 

 

 

 

 

 

 

 

 

 

 

65

 

Release of restricted stock units

 

 

12

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,285

 

 

 

 

 

 

 

 

 

1,285

 

Exercise of common stock options

 

 

5

 

 

 

8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

8

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9,753

)

 

 

(9,753

)

Foreign currency translation

  adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

45

 

 

 

 

 

 

45

 

Balance, March 31, 2018

 

 

59,876

 

 

$

206,163

 

 

 

116

 

 

$

218

 

 

$

41,807

 

 

$

(527

)

 

$

(244,130

)

 

$

3,531

 

 

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balance, December 31, 2018

 

 

76,336

 

 

$

229,019

 

 

$

44,111

 

 

$

(575

)

 

$

(269,471

)

 

$

3,084

 

Adoption of ASC Topic 842-Leases (see note 2)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(144

)

 

 

(144

)

Issuance of shares of common stock and warrants in

   connection with rights offering, net of issuance

   costs

 

 

47,812

 

 

 

34,399

 

 

 

 

 

 

 

 

 

 

 

 

34,399

 

Release of restricted stock units

 

 

50

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrants modification (see note 7)

 

 

 

 

 

 

 

 

1,577

 

 

 

 

 

 

(1,577

)

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

898

 

 

 

 

 

 

 

 

 

898

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9,700

)

 

 

(9,700

)

Foreign currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

(8

)

 

 

 

 

 

(8

)

Balance, March 31, 2019

 

 

124,198

 

 

$

263,418

 

 

$

46,586

 

 

$

(583

)

 

$

(280,892

)

 

$

28,529

 

 

See accompanying notes.

6


 

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Condensed Consolidated Statements of Cash Flows

(in thousands)

 

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

 

 

(unaudited)

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(9,700

)

 

$

(9,753

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

99

 

 

 

111

 

Stock-based compensation

 

 

898

 

 

 

1,285

 

Non-cash lease expense

 

 

6

 

 

 

 

Inventory reserve

 

 

 

 

 

(109

)

Impairment charge

 

 

2,424

 

 

 

 

Common stock issuance for services

 

 

 

 

 

65

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(95

)

 

 

1,374

 

Inventories

 

 

(786

)

 

 

21

 

Prepaid expenses and other assets

 

 

236

 

 

 

(16

)

Accounts payable

 

 

297

 

 

 

857

 

Accrued expenses

 

 

(57

)

 

 

(354

)

Accrued compensation expenses

 

 

(609

)

 

 

(534

)

Accrued clinical trial expenses

 

 

84

 

 

 

161

 

Contract liabilities

 

 

53

 

 

 

114

 

Net cash used in operating activities

 

 

(7,150

)

 

 

(6,778

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(37

)

 

 

(68

)

Net cash used in investing activities

 

 

(37

)

 

 

(68

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Net proceeds from sale of common stock and warrants

 

 

34,399

 

 

 

3,992

 

Proceeds from exercise of options and warrants

 

 

 

 

 

15

 

Net cash provided by financing activities

 

 

34,399

 

 

 

4,007

 

Effect of exchange rate changes on cash and cash equivalents

 

 

(1

)

 

 

14

 

Cash and cash equivalents:

 

 

 

 

 

 

 

 

Net increase (decrease)

 

 

27,211

 

 

 

(2,825

)

Balance at beginning of period

 

 

4,471

 

 

 

7,839

 

Balance at end of period

 

$

31,682

 

 

$

5,014

 

 

See accompanying notes.

7


 

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

1. Organization and Business Operations

Second Sight Medical Products, Inc. (“Second Sight,” “we,” “us,” or “the Company”) was incorporated in the State of California in 2003. Second Sight develops, manufactures and markets implantable visual prosthetics to enable blind individuals to achieve greater independence.

In 2007, Second Sight formed Second Sight Medical Products (Switzerland) Sàrl, initially to manage clinical trials for its products in Europe, and later to manage sales and marketing in Europe, the Middle East and Asia-Pacific. As the laws of Switzerland require at least two corporate stockholders, Second Sight Medical Products (Switzerland) Sàrl is 99.5% owned directly by us and 0.5% owned by an executive of Second Sight as of March 31, 2019. Accordingly, Second Sight Medical Products (Switzerland) Sàrl is considered 100% owned for financial statement purposes and is consolidated with Second Sight for all periods presented.

We are currently developing the Orion® Visual Cortical Prosthesis System (“Orion”), an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma. A feasibility study of the Orion device is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles (“UCLA”) and Baylor College of Medicine in Houston (“Baylor”).

Our commercial product, the Argus® II retinal prosthesis system (“Argus II”), entered clinical trials in 2006, received CE Mark approval for marketing and sales in the European Union (“EU”) in 2011, and received approval by the United States Food and Drug Administration (“FDA”) for marketing and sales in the United States in 2013. We began selling the Argus II in Europe at the end of 2011, Saudi Arabia in 2012, the United States and Canada in 2014, Turkey in 2015, Iran, Taiwan, South Korea and Russia in 2017, and Singapore in 2018. Given the limited addressable market of Argus II, we have made the decision to maximize capital efficiency with our Argus commercial and clinical activities and increase our investment of resources with our Orion clinical and R&D programs.

Liquidity and Going Concern

From inception, our operations have been funded primarily through the sales of our common stock and warrants, as well as from the issuance of convertible debt, research and clinical grants, and limited product revenue generated from the sale of our Argus II product. Funding of our business since 2018 has been provided by:

         

 

 

Issuance of common stock through our At Market Issuance Sales Agreement (the “Sales Agreement”) during the first quarter        of 2018 which provided net cash proceeds of $4.0 million.

 

Issuance of common stock in a securities purchase agreement in May 2018, which provided net cash proceeds of $10.0 million.

 

Issuance of common stock in a securities purchase agreement in August 2018, which provided net cash proceeds of $5.0 million.

 

Issuance of common stock in a securities purchase agreement in October 2018, which provided net cash proceeds of $4.0 million.

 

Issuance of common stock in a securities purchase agreement in December 2018, which provided net cash proceeds of $3.0 million.

 

Issuance of common stock and warrants in a rights offering in February 2019, which provided net cash proceeds of $34.4 million.

 

Revenue of $1.1 million for the three months ended March 31, 2019 and $6.9 million for the year ended December 31, 2018 generated by sales of our Argus II product.

              

                                                 

8


 

In November 2017, we entered into an At Market Issuance Sales Agreement with B. Riley FBR Inc. and H.C. Wainwright & Co., LLC, as agents (“Agents”) pursuant to which we may offer and sell, from time to time through either of the Agents, shares of our common stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the SEC. We agreed to pay the Agents a cash commission of 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. During January and February 2018, we sold 2.2 million shares of common stock which provided net proceeds of $4.0 million under the Sales Agreement. No shares have been sold since February 2018 under the Sales Agreement.

In a rights offering completed on February 22, 2019, we sold approximately 47.8 million units, each priced at $0.724 for gross proceeds of approximately $34.6 million. Each unit consisted of one share and one immediately exercisable warrant having an exercise price of $1.47 per share. Entities controlled by Gregg Williams, our Chairman of the Board of Directors, acquired approximately 41.4 million units in the offering for an aggregate investment of approximately $30 million.

On January 25, 2019, we received a letter from The Nasdaq Stock Market advising us that for 30 consecutive trading days preceding the date of the letter, the bid price of our common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to listing rules, and therefore we could become subject to delisting if we did not regain compliance within the compliance period (or the compliance period as may be extended). We continue to monitor and evaluate our options to cure this deficiency within the compliance period.

Our financial statements have been presented on the basis that our business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with one product line and limited commercial product revenues, including limitations on our operating capital resources and uncertain demand for our products. We have incurred recurring operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future.

We do not have sufficient funds to support our operations for the next 12 months from the date of issuance of these financial statements. Accordingly, these and other related factors raise substantial doubt about our ability to continue as a going concern. We anticipate that we will seek to additionally fund our operations through public or private equity or debt financings, grants, collaborations, strategic partnerships or other sources. However, we may be unable to raise additional capital or enter into such other arrangements when needed on favorable terms or at all. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or any other approved product candidates, or we may be unable to expand our operations, maintain our current organization and employee base or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

2. Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements

Basis of Presentation

These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. Certain prior year amounts have been reclassified to conform to the current year presentation. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2018, contained in our Annual Report on Form 10-K filed with the SEC on March 18, 2019. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.

Significant Accounting Policies

 

    

Discontinued operations

 

       Based upon our decision on May 10, 2019 to accelerate our transition to the Orion platform, we evaluated our accounting policies related to the disposition in accordance with ASC 205-20 Discontinued Operations, and assessed our long-lived assets for any indications that their carrying values may not be recoverable in accordance with ASC 360, Property, Plant, and Equipment, for any impairment. Based upon these reviews we recorded an impairment charge of $2.4 million related to inventory of Argus II based on our plans to suspend production of Argus II. Based upon our review of the applicable accounting standards we determined that there was no impairment of any other assets.

Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2018.

9


 

Recently Adopted Accounting Pronouncements

We adopted ASU No. 2016-02—Leases (Topic 842), as amended, as of January 1, 2019, using the modified retrospective approach. The modified retrospective approach provides a method for recording existing leases at the period of adoption without restating prior comparative periods which is the method we have chosen. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification. Adoption of the new standard resulted in the recording of right-of-use assets and operating lease liabilities of approximately $2.6 million and $2.8 million respectively, as of January 1, 2019. The difference of $0.2 million between the right-of-use assets and operating lease liabilities, net of the deferred tax impact, was recorded as an adjustment to accumulated deficit at January 1, 2019. The standard did not materially impact our consolidated net earnings and had no impact on cash flows.

       We do not believe that any other recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

3. Concentration of Risk

Credit Risk

Financial instruments that subject us to concentrations of credit risk consist primarily of cash, money market funds, and trade accounts receivable. We maintain cash and money market funds with financial institutions that we deem reputable. We extend differing levels of credit to our customers, and typically do not require collateral.

Customer Concentration

The following tables provide information about disaggregated revenue by service type, customer and geographical market.

The following table shows our revenues by customer type during the three months ended March 31, 2019 and 2018:

 

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

Direct channel

 

$

946

 

 

$

659

 

Indirect channel

 

 

182

 

 

 

317

 

 

 

$

1,128

 

 

$

976

 

 

During the three months ended March 31, 2019 and 2018, the following customers each comprised greater than 10% of our total revenues:

 

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

Customer 1

 

 

23

%

 

 

15

%

Customer 2

 

 

15

%

 

 

14

%

Customer 3

 

 

13

%

 

 

%

Customer 4

 

 

12

%

 

 

%

Customer 5

 

 

12

%

 

 

%

Customer 6

 

 

10

%

 

 

11

%

Customer 7

 

 

10

%

 

 

%

Customer 8

 

 

%

 

 

22

%

Customer 9

 

 

%

 

 

12

%

Customer 10

 

%

 

11

%

 

10


 

As of March 31, 2019 and December 31, 2018, the following customers each comprised greater than 10% of our total accounts receivable:

 

 

 

March 31,

2019

 

 

December 31, 2018

 

Customer 1

 

 

28

%

 

 

%

Customer 2

 

 

24

%

 

 

22

%

Customer 3

 

 

23

%

 

 

21

%

Customer 4

 

 

22

%

 

%

Customer 5

 

%

 

55

%

 

 

 

 

 

 

 

 

Geographic Concentration

During the three months ended March 31, 2019 and 2018, regional revenue based on customer locations which each comprised greater than 10% of our total revenues, consisted of the following:

 

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

United States

 

 

60

%

 

 

53

%

Italy

 

 

23

%

 

 

15

%

Korea

 

 

10

%

 

 

11

%

Singapore

 

 

%

 

 

12

%

 

 

 

 

 

 

 

 

 

Foreign Operations

The accompanying condensed consolidated financial statements as of March 31, 2019 and December 31, 2018 both include assets amounting to $1.5 million relating to operations of our subsidiary based in Switzerland. It is possible that unanticipated events in foreign countries could disrupt our operations.

4. Fair Value Measurements

The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.

Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.

Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.

Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.

Cash equivalents which includes money market funds are the only financial instrument measured and recorded at fair value on our consolidated balance sheet, and they are valued using Level 1 inputs.

Assets measured at fair value on a recurring basis are as follows (in thousands):

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

March 31, 2019 (unaudited):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

31,335

 

 

$

31,335

 

 

$

 

 

$

 

December 31, 2018:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

4,156

 

 

$

4,156

 

 

$

 

 

$

 

 

       As of March 31, 2019 and December 31, 2018, the money market funds include $0.2 million held in a deposit account in Switzerland as security for the performance of contracts.

11


 

 

5. Selected Balance Sheet Detail

Inventories, net

Inventories consisted of the following (in thousands):

 

 

 

March 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

Raw materials

 

$

791

 

 

$

791

 

Work in process

 

 

2,512

 

 

 

3,055

 

Finished goods

 

 

2,705

 

 

 

2,089

 

 

 

 

6,008

 

 

 

5,935

 

Allowance for excess and obsolete inventory and impairment charge

 

 

(4,406

)

 

 

(2,685

)

Inventories, net

 

$

1,602

 

 

$

3,250

 

 

 

       We recorded $2.4 million as an impairment charge in the first quarter of 2019, related to our plans to suspend Argus II production. See note 10 for further details.

 

Property and equipment

Property and equipment consisted of the following (in thousands):

 

 

 

March 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

Laboratory equipment

 

$

2,482

 

 

$

2,482

 

Computer hardware and software

 

 

1,493

 

 

 

1,456

 

Leasehold improvements

 

 

298

 

 

 

298

 

Furniture, fixtures and equipment

 

 

46

 

 

 

46

 

 

 

 

4,319

 

 

 

4,282

 

Accumulated depreciation and amortization

 

 

(3,356

)

 

 

(3,257

)

Property and equipment, net

 

$

963

 

 

$

1,025

 

 

Contract Liabilities

Contract liabilities consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

Beginning balance as of December 31, 2018

 

$

167

 

 

 

        Consideration received in advance of revenue recognition

 

 

51

 

 

 

        Revenue recognized

 

 

 

 

 

Ending Balance as of March 31, 2019

 

$

218

 

 

 

 

Allowance for Doubtful Accounts

Allowance for doubtful accounts consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

Beginning balance as of December 31, 2018

 

$

181

 

 

 

        Additions

 

 

 

 

 

        (Write-offs) Recoveries

 

 

(1

)

 

 

Ending Balance as of March 31, 2019

 

$

180

 

 

 

      

       Right-of-use assets and operating lease liabilities

 

      We lease certain office space and equipment for our use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease costs are recognized in the income statement over the lease term on a straight-line basis. Operating leases with a term of one year or less are recognized on a straight line basis over the term. Depreciation is computed using the straight-line method over the estimated useful life of the respective assets. Our operating lease for office space includes one option to renew, with a five year renewal term that can extend the lease term to 2027. The exercise of this lease renewal option is at our sole discretion. The depreciable

12


 

life of assets and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. As most of our leases do not provide an implicit rate, we used our estimated incremental borrowing rate of 10% based on the information available at commencement date in determining the present value of lease payments.

 

 

       Lease assets and liabilities consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

 

 

Assets

Classification

March 31,
2019

 

 

 

      Non-current assets

Right-of-use assets

$

       2,508

 

 

 

 

Liabilities

 

 

 

  Current

Current operating lease liabilities

$

         210

 

 

 

 

      Long term

Long term operating lease liabilities

$         2,586

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

:

The components of lease expense for the three months ended March 31, 2019 were as follows (unaudited):

 

 

 

 

 

 

 

 

For the three months ended
March 31, 2019

 

 

 

 

 

Lease expense:

 

  

 

 

 

 

 

 

 

Operating lease expense

 

$

123

 

 

 

 

 

 

Short-term lease expense

 

 

 

 

 

 

Total lease expense

 

$

123

 

 

 

 

 

 

 

Other information:

 

 

 

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

 

Operating cash flows from operating leases

 

$

117

 

 

 

 

 

 

For operating lease:

 

 

 

 

Weighted average remaining lease term (in years)

 

 

7.9

 

Weighted average discount rate

 

 

10

%

 

Minimum future payments under the Company’s leases at March 31, 2019 and their application to the corresponding lease liabilities are as follows (unaudited):

 

 

 

Discounted lease
liability payments

 

 

Payments due
under lease
agreements

 

2019 (remaining nine months)

 

$

155  

 

 

$

359

 

2020

 

 

237

 

 

 

491

 

2021

 

 

277

 

 

 

505

 

2022

 

 

322

 

 

 

521

 

2023

 

 

352

 

 

 

516

 

Thereafter

 

 

1,453

 

 

 

1,704

 

Total

 

$

2,796

 

 

$

4,096

 

 

13


 

6. Equity Securities

Potentially Dilutive Common Stock Equivalents

As of  March 31, 2019 and 2018, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive (in thousands).

 

 

 

March 31,

 

 

 

2019

 

 

2018

 

Common stock warrants issued to underwriter of initial public offering

 

 

802

 

 

 

802

 

Common stock warrants issued in connection with March 2017 rights offering

 

 

13,647

 

 

 

13,647

 

Common stock warrants issued in connection with February 2019 rights offering

 

 

47,812

 

 

 

 

Common stock options

 

 

8,587

 

 

 

7,921

 

Common stock issuable

 

 

 

 

 

116

 

Restricted stock units

 

 

513

 

 

 

71

 

Employee stock purchase plan

 

 

451

 

 

 

229

 

 

 

 

71,812

 

 

 

22,786

 

 

7. Warrants

Warrants to purchase 47,812,371 shares of common stock with an exercise price of $1.47 per share were issued in the rights offering completed in February 2019.  The warrants are listed for trading under the symbol “EYESW” on the NASDAQ Capital Market and expire on March 14, 2024.

At the Company’s discretion, the warrants are redeemable on 30 days’ notice (i) if, after March 14, 2019, the shares of the Company’s common stock are trading at $2.94 for 15 consecutive trading days and (ii) if all of the independent directors vote in favor of redeeming the warrants. Holders may be able to sell or exercise warrants prior to any announced redemption date and the Company will redeem outstanding warrants not exercised by the announced redemption date for a nominal amount of $0.01 per Warrant.

The net cash proceeds were allocated to the relative fair values of the common stock and warrants on the date of issuance resulting in an allocation of $0.47 per share to the common stock and $0.25 per share to the warrants. In calculating the fair value of the warrants using the Black-Scholes model, the assumptions included a risk free interest rate of 2.49%, expected volatility of 82% and expected life of 5.08 years, and a 0% dividend yield.

We extended the term of 13,647,286 warrants issued in our March 2017 rights offering (“March 2017 warrants”) by approximately two years effective as of February 15, 2019 as part of our February 2019 rights offering. We determined the fair value of the March 2017 warrants immediately before and after the modification. The fair value of the March 2017 warrants after the modification was increased by approximately $1.6 million, resulting in an accounting adjustment to additional paid-in capital and accumulated deficit in the consolidated statements of shareholders’ equity. The assumptions used in the determination of fair value of the warrants before and after the extension included a risk free interest rate of 2.50% and 2.49%, expected volatility of 81% and 82%, and expected lives of 3.08 years and 5.08 years, respectively and 0% dividend yields for both.

    

A summary of warrants activity for the three months ended March 31, 2019 is presented below (in thousands, except per share and contractual life data).

 

 

 

Number of

Shares

 

 

Weighted

Average

Exercise

Price

Per Share

 

 

Weighted

Average

Remaining

Contractual

Life (in Years)

 

Warrants outstanding as of December 31, 2018

 

 

14,449

 

 

$

2.01

 

 

 

3.10

 

        Issued

 

 

47,812

 

 

 

1.47

 

 

 

 

 

        Exercised

 

 

 

 

 

 

 

 

 

 

 

        Forfeited or expired

 

 

 

 

 

 

 

 

 

 

 

Warrants outstanding as of March 31, 2019

 

 

62,261

 

 

$

1.60

 

 

 

4.90

 

Warrants exercisable as of March 31, 2019

 

 

62,261

 

 

$

1.60

 

 

 

4.90

 

 

The warrants outstanding as of March 31, 2019 had no intrinsic value.

14


 

8. Stock-Based Compensation

A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the three months ended March 31, 2019 is presented below (in thousands, except per share and contractual life data).